Guardant Health, Inc. $GH Shares Bought by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 27.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 415,774 shares of the company’s stock after purchasing an additional 88,491 shares during the period. Guardant Health makes up 1.3% of Emerald Mutual Fund Advisers Trust’s investment portfolio, making the stock its 21st largest position. Emerald Mutual Fund Advisers Trust’s holdings in Guardant Health were worth $21,637,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares during the last quarter. SVB Wealth LLC acquired a new position in shares of Guardant Health in the 1st quarter valued at $54,000. FNY Investment Advisers LLC acquired a new position in shares of Guardant Health in the 2nd quarter valued at $62,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Guardant Health in the 1st quarter valued at $97,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares in the company, valued at $126,242,015.55. This represents a 12.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director owned 851 shares in the company, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 302,691 shares of company stock worth $17,984,628. 6.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GH has been the topic of several recent analyst reports. Raymond James Financial upped their price target on Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, July 31st. Piper Sandler upped their price target on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Stifel Nicolaus set a $73.00 price objective on Guardant Health in a report on Thursday, September 25th. Evercore ISI boosted their price objective on Guardant Health from $60.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, September 25th. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $68.90.

Guardant Health Trading Up 3.9%

GH stock opened at $72.27 on Thursday. The company has a market capitalization of $9.01 billion, a PE ratio of -21.57 and a beta of 1.53. Guardant Health, Inc. has a 12-month low of $21.28 and a 12-month high of $73.31. The business’s fifty day moving average price is $62.98 and its 200 day moving average price is $52.54.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.26). During the same period in the prior year, the firm posted ($0.88) earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.